Compare RBC & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBC | EXAS |
|---|---|---|
| Founded | 1919 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 11.0B |
| IPO Year | 2005 | N/A |
| Metric | RBC | EXAS |
|---|---|---|
| Price | $442.80 | $101.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | ★ $441.17 | $76.38 |
| AVG Volume (30 Days) | 163.2K | ★ 9.8M |
| Earning Date | 10-31-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.54 | N/A |
| EPS | ★ 8.20 | N/A |
| Revenue | $1,723,400,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $14.28 | $16.68 |
| Revenue Next Year | $10.86 | $12.36 |
| P/E Ratio | $53.86 | ★ N/A |
| Revenue Growth | 8.27 | ★ 14.47 |
| 52 Week Low | $290.56 | $38.81 |
| 52 Week High | $449.60 | $101.87 |
| Indicator | RBC | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 64.88 | 90.52 |
| Support Level | $418.05 | $101.01 |
| Resistance Level | $449.60 | $101.61 |
| Average True Range (ATR) | 11.10 | 2.63 |
| MACD | -0.33 | 1.94 |
| Stochastic Oscillator | 79.68 | 98.21 |
RBC Bearings Inc is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: Industrial, which derives maximum revenue, and Aerospace/Defense. The Aerospace/Defense segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the Industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.